APA (7th ed.) Citation

Tian, Y., Lei, T., Ruan, Q., Zhou, X., Shen, R., Xie, T., . . . Chen, M. (2026). Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study. Cancer Medicine, 15(4), 1. https://doi.org/10.1002/cam4.71756

Chicago Style (17th ed.) Citation

Tian, Yitong, Tian Lei, Qingyang Ruan, Xueying Zhou, Ruijing Shen, Tianao Xie, Shijie Li, Xiujun Cai, and Mingyu Chen. "Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study." Cancer Medicine 15, no. 4 (2026): 1. https://doi.org/10.1002/cam4.71756.

MLA (9th ed.) Citation

Tian, Yitong, et al. "Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High‐Risk Recurrence Factors: A Phase II Single‐Center Prospective Study." Cancer Medicine, vol. 15, no. 4, 2026, p. 1, https://doi.org/10.1002/cam4.71756.